Literature DB >> 3557438

Amiodarone lung: pathologic findings in clinically toxic patients.

J L Myers, J I Kennedy, V J Plumb.   

Abstract

Lung biopsy and autopsy specimens of 12 patients with amiodarone pulmonary toxicity were studied to better characterize the pathology of amiodarone lung. For comparison, the autopsy specimens of five patients taking amiodarone without pulmonary side effects also were examined. Interstitial pneumonia was the most common manifestation of amiodarone lung and was characterized by interstitial inflammation, fibrosis, and hyperplasia of type II pneumocytes. Hyaline membranes were present in two cases. Foamy alveolar macrophages were present in all but one patient, and in four associated organizing pneumonia was present. Foamy alveolar macrophages also were present in three of five clinically nontoxic patients. Electron microscopy demonstrated membrane-bound lamellar inclusions in all of the three cases of amiodarone lung examined. Inclusions also were present in two of five patients who died of other causes. The authors conclude that amiodarone lung is primarily an interstitial pneumonia. Foamy alveolar macrophages and cytoplasmic lamellar inclusions are characteristic, but neither is specific, and their presence alone does not distinguish toxic from nontoxic patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3557438     DOI: 10.1016/s0046-8177(87)80164-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

Review 1.  Organising pneumonia.

Authors:  J F Cordier
Journal:  Thorax       Date:  2000-04       Impact factor: 9.139

2.  Interstitial pneumonitis with accumulation of intraalveolar macrophages, a facet amiodarone therapy.

Authors:  Lorenz H Lehmann; Wilko Weichert; Dirk Schnapauff; Rainer Dietz; Martin Stockburger
Journal:  Clin Res Cardiol       Date:  2008-10-31       Impact factor: 5.460

3.  [Medical therapy of heart and lung diseases. Effects on the respective other organ].

Authors:  S Möhlenkamp; G Weinreich; T Neumann; T Voshaar; H Teschler
Journal:  Herz       Date:  2014-02       Impact factor: 1.443

4.  Prospective evaluation of drug-induced lung toxicity with high-resolution CT and transbronchial biopsy.

Authors:  S Piciucchi; M Romagnoli; M Chilosi; C Bigliazzi; A Dubini; B Beomonte Zobel; G Gavelli; A Carloni; V Poletti
Journal:  Radiol Med       Date:  2010-12-03       Impact factor: 3.469

5.  Bronchiolitis obliterans organising pneumonia in patients taking acebutolol or amiodarone.

Authors:  P Camus; J N Lombard; M Perrichon; F Piard; J C Guérin; F B Thivolet; L Jeannin
Journal:  Thorax       Date:  1989-09       Impact factor: 9.139

6.  Severe amiodarone induced pulmonary toxicity.

Authors:  Nicholas Nacca; Castigliano M Bhamidipati; Luke S Yuhico; Sowmya Pinnamaneni; Tamas Szombathy
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

Review 7.  Amiodarone pulmonary toxicity.

Authors:  N Wolkove; M Baltzan
Journal:  Can Respir J       Date:  2009 Mar-Apr       Impact factor: 2.409

8.  [Amiodarone-induced pneumonitis. Lethal complication in a patient after thoracic surgery].

Authors:  V Ghezel-Ahmadi; V C Kürschner; A Fisseler-Eckhoff; J Schirren; J E Schmitz; T Obenhaus
Journal:  Anaesthesist       Date:  2008-10       Impact factor: 1.041

Review 9.  Hemokinins and endokinins.

Authors:  N M Page
Journal:  Cell Mol Life Sci       Date:  2004-07       Impact factor: 9.261

Review 10.  [Amiodarone-induced pulmonary toxicity].

Authors:  A Heisel; M Berg; M Stopp; D Ukena; H Schieffer
Journal:  Med Klin (Munich)       Date:  1997-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.